Meso Scale Discovery® Electrochemilumine scence (MSD-ECL)

Ultra-Sensitive Detection to Support Your Multiplexing Needs

BioAgilytix leverages the Meso Scale Discovery Electrochemiluminescence (MSD-ECL) platform and its plate-based electrochemiluminescence technology to provide reliable, high-quality data for a diverse variety of biological assays used for the development of biologics and cell and gene therapies. MSD is particularly well-suited for those assays with high sensitivity and high tolerance to circulating antigen.

BioAgilytix is one of the first labs with the experience to successfully leverage the Mesoscale Discovery (MSD) S-Plex Proinflammatory Panel 1 platform to measure a validated panel of immune-derived biomarkers. The panel was already validated in both human serum and plasma, providing sponsors with accelerated access to sample results and time savings for their programs. The increased sensitivity of the S-Plex platform allows shifts in the dynamic range of assays, resulting in low detection limits. This enables detection of multiple analytes in samples not readily detected by other assay formats.

Learn More About the MSD Platform:

Still have questions?

BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.


The MSD-ECL platform uses electrochemiluminescent labels that are conjugated to detection antibodies. These labels generate light when stimulated by electricity in the appropriate chemical environment, which can then be used to measure key proteins and molecules.

The detection process is initiated at electrodes located in the bottom of the platform’s microplates, and only labels near the electrode are excited and detected. Electricity is applied to the plate electrodes, leading to light emission by SULFO-TAG labels, which are electrochemiluminescent labels that allow for ultra-sensitive detection. Light intensity is then measured to quantify analytes in the sample. The MSD-ECL platform employs buffers with high concentrations of Tripropylamine as a catalyst for a dual redox reaction with Ruthenium, emitting light at 620 nm.

Why BioAgilytix for Small and Large Molecule Bioanalysis?

Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.


BioAgilytix’s scientists most frequently utilize Meso Scale Discovery (MSD-ECL) in our work with biomarkersimmunogenicitypharmacokinetics (PK)cell-based assays, and lot release testing, as well as for the bioanalysis of cell and gene therapies – which could include evaluation of antibodies to specific HLA haplotype expressed by allogenous cell therapy and immunogenicity assessments for the vector, transgene, and lipid nanoparticle used in these compounds. We are able to run MSD assays in support of non-GLP, GLP, and product release testing under GMP.